Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing

William W. Hope; Peter A. Warn; Andrew Sharp; Paul Reed; Brian Keevil; Arnold Louie; Thomas J. Walsh; David W. Denning; George L. Drusano

doi:10.1128/AAC.00488-07

Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing

William W. Hope, Peter A. Warn, Andrew Sharp, Paul Reed, Brian Keevil, Arnold Louie, Thomas J. Walsh, David W. Denning, George L. Drusano

Research output: Contribution to journal › Article › peer-review

Abstract

Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect. Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Original language	English
Pages (from-to)	3760-3762
Number of pages	2
Journal	Antimicrobial Agents and Chemotherapy
Volume	51
Issue number	10
DOIs	https://doi.org/10.1128/AAC.00488-07
Publication status	Published - Oct 2007

Keywords

Algorithms
Amphotericin B/pharmacokinetics/*therapeutic use
Antibiotics, Antifungal/pharmacokinetics/*therapeutic use
Antifungal Agents/*administration & dosage/pharmacokinetics/*therapeutic
use
Area Under Curve
Candidiasis/*drug therapy/microbiology
Child
Drug Interactions
Flucytosine/*administration & dosage/pharmacokinetics/*therapeutic use
Humans
Models, Statistical
Monte Carlo Method

Access to Document

10.1128/AAC.00488-07

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17682101

Cite this

Hope, W. W., Warn, P. A., Sharp, A., Reed, P., Keevil, B., Louie, A., Walsh, T. J., Denning, D. W., & Drusano, G. L. (2007). Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing. Antimicrobial Agents and Chemotherapy, 51(10), 3760-3762. https://doi.org/10.1128/AAC.00488-07

@article{d8738aaa0b774ef8948d3c31e4f3112f,

title = "Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing",

abstract = "Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect. Copyright {\textcopyright} 2007, American Society for Microbiology. All Rights Reserved.",

keywords = "Algorithms, Amphotericin B/pharmacokinetics/*therapeutic use, Antibiotics, Antifungal/pharmacokinetics/*therapeutic use, Antifungal Agents/*administration & dosage/pharmacokinetics/*therapeutic, use, Area Under Curve, Candidiasis/*drug therapy/microbiology, Child, Drug Interactions, Flucytosine/*administration & dosage/pharmacokinetics/*therapeutic use, Humans, Models, Statistical, Monte Carlo Method",

author = "Hope, {William W.} and Warn, {Peter A.} and Andrew Sharp and Paul Reed and Brian Keevil and Arnold Louie and Walsh, {Thomas J.} and Denning, {David W.} and Drusano, {George L.}",

year = "2007",

month = oct,

doi = "10.1128/AAC.00488-07",

language = "English",

volume = "51",

pages = "3760--3762",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "10",

}

TY - JOUR

T1 - Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing

AU - Hope, William W.

AU - Warn, Peter A.

AU - Sharp, Andrew

AU - Reed, Paul

AU - Keevil, Brian

AU - Louie, Arnold

AU - Walsh, Thomas J.

AU - Denning, David W.

AU - Drusano, George L.

PY - 2007/10

Y1 - 2007/10

N2 - Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect. Copyright © 2007, American Society for Microbiology. All Rights Reserved.

AB - Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect. Copyright © 2007, American Society for Microbiology. All Rights Reserved.

KW - Algorithms

KW - Amphotericin B/pharmacokinetics/therapeutic use

KW - Antibiotics, Antifungal/pharmacokinetics/therapeutic use

KW - Antifungal Agents/administration & dosage/pharmacokinetics/therapeutic

KW - use

KW - Area Under Curve

KW - Candidiasis/drug therapy/microbiology

KW - Child

KW - Drug Interactions

KW - Flucytosine/administration & dosage/pharmacokinetics/therapeutic use

KW - Humans

KW - Models, Statistical

KW - Monte Carlo Method

U2 - 10.1128/AAC.00488-07

DO - 10.1128/AAC.00488-07

M3 - Article

C2 - 17682101

SN - 0066-4804

VL - 51

SP - 3760

EP - 3762

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 10

ER -

Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: A pharmacodynamic rationale for reduced dosing

Abstract

Keywords

Access to Document

Fingerprint

Cite this